Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Investigating the safety and efficacy of re-treating CLL patients with venetoclax-based regimens

In this video, Paula Cramer, MD, University of Cologne, Cologne, Germany, shares some results from a study evaluating the safety and efficacy of re-treating chronic lymphocytic leukemia (CLL) patients with venetoclax-based regimens following relapse. Dr Cramer first explains the rationale behind this study, and then discusses the patient population enrolled. Following this, Dr Cramer highlights the results obtained, which suggest that re-treatment with venetoclax-based regimens appears to be safe and efficacious, with no increase in adverse events (AEs). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.